Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Daniel J. DeAngelo, MD, PhD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chief, Division of Leukemia
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • CAR T-cell therapy
  • Leukemias
  • Mastocytosis
  • Myelodysplastic syndromes
  • Myeloproliferative disorders

Diseases Treated

Contact Information

  • Appointments617-632-6028 (new)
    617-582-7386 x1 (follow-up)
  • Office Phone Number617-582-8410
  • Fax617-632-6771

Bio

Dr. DeAngelo received his MD and PhD from Albert Einstein College of Medicine in 1993, followed by residency in internal medicine at Massachusetts General Hospital. He served a clinical fellowship in hematology and oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.

Board Certification:

  • Hematology, 2000
  • Internal Medicine
  • Medical Oncology, 1999

Fellowship:

  • Brigham and Women's Hospital, Hematology & Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Albert Einstein College of Medicine

Research

Treating Leukemias, Myelodysplasia, and Myeloproliferative Disorders

The Adult Leukemia Group is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplastic syndrome (MDS), and other stem cell hematopoietic disorders. Our clinical research centers around phase I, II, and III clinical trials in these patients.We recently studied a series of patients with idiopathic hypereosinophilic syndrome (IHES). In collaboration with Drs. Cools and Gilliland, we identified a target gene, the FIP1L1-PDGFRA fusion gene, which is a consequence of an interstitial chromosomal deletion. This finding has led to the explanation of the molecular basis of IHES.Our group is currently working on the development of small molecules to treat acute and chronic leukemias and myelodysplasia. We are testing several small molecules in patients with relapsed or refractory acute myelogenous leukemia, studying the compounds PKC-412, CEP-701, and MLN-518 that specifically inhibit FLT3. Mutations in the FLT3 gene, which encodes a receptor tyrosine kinase, are thought to confer a poor prognosis in patients with acute myelogenous leukemia. We also have clinical trials under way that test histone deacetylase inhibitors in advanced hematologic malignancies. Our approach is to bring novel therapeutic agents to the forefront in the treatment of patients with acute and chronic leukemia, MDS, and myeloproliferative disorders.In addition, our group has been focused on the treatment of acute lymphoblastic leukemia (ALL). We are the lead coordinating site for a large clinical trial using dose-intense pediatric-like regimens for adult patients with ALL. We are also testing novel Notch inhibitor molecules for patients with relapsed or refractory T-cell ALL.

Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 Oct 06.
View in: PubMed

Orthopedic Toxicities Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials. Blood Adv. 2021 Oct 05.
View in: PubMed

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Adv. 2021 Sep 29.
View in: PubMed

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2021 Sep 20.
View in: PubMed

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 09 20; 19(9):1079-1109.
View in: PubMed

The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 Sep 09; 138(10):898-911.
View in: PubMed

Racial and Ethnic Enrollment Disparities and Demographic Reporting Requirements in Acute Leukemia Clinical Trials. Blood Adv. 2021 Sep 02.
View in: PubMed

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Hemasphere. 2021 Aug; 5(8):e617.
View in: PubMed

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22.
View in: PubMed

Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica. 2021 07 01; 106(7):1787-1793.
View in: PubMed

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 08 07; 398(10299):491-502.
View in: PubMed

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 May 06; 137(18):2463-2480.
View in: PubMed

Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol. 2021 07 01; 96(7):E259-E262.
View in: PubMed

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
View in: PubMed

Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021 03 31; 13(587).
View in: PubMed

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9.
View in: PubMed

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 May 15; 27(10):2742-2754.
View in: PubMed

A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2021 07; 62(7):1740-1748.
View in: PubMed

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 03 15; 127(6):905-913.
View in: PubMed

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175.
View in: PubMed

Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer. 2021 02 01; 127(3):372-380.
View in: PubMed

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 10 01; 18(10):1385-1415.
View in: PubMed

Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S44-S47.
View in: PubMed

Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Transl Sci. 2021 01; 14(1):184-193.
View in: PubMed

Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.
View in: PubMed

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer J. 2020 08 07; 10(8):81.
View in: PubMed

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug; 7(8):e601-e612.
View in: PubMed

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020 08; 61(8):2012-2015.
View in: PubMed

Recent Advances in Managing Acute Lymphoblastic Leukemia. Am Soc Clin Oncol Educ Book. 2020 May; 40:330-342.
View in: PubMed

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020 04 28; 4(8):1683-1689.
View in: PubMed

The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost. 2020 02; 18(2):278-284.
View in: PubMed

Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Mod Pathol. 2020 06; 33(6):1135-1145.
View in: PubMed

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. Am J Hematol. 2020 03; 95(3):245-250.
View in: PubMed

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 12 12; 381(24):2315-2326.
View in: PubMed

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
View in: PubMed

Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. Leuk Res Rep. 2019; 12:100189.
View in: PubMed

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
View in: PubMed

Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia. ACG Case Rep J. 2019 Aug; 6(8):e00207.
View in: PubMed

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123.
View in: PubMed

Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leuk Res. 2019 10; 85:106197.
View in: PubMed

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 09 12; 134(11):867-879.
View in: PubMed

Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
View in: PubMed

Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. J Natl Compr Canc Netw. 2019 05 01; 17(5):414-423.
View in: PubMed

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2019 09; 25(9):1720-1729.
View in: PubMed

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
View in: PubMed

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
View in: PubMed

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling. Br J Clin Pharmacol. 2019 03; 85(3):590-600.
View in: PubMed

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019 04; 94(4):408-416.
View in: PubMed

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018 12 27; 11(1):143.
View in: PubMed

Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. J Neuropathol Exp Neurol. 2018 10 01; 77(10):877-882.
View in: PubMed

New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 2018 Sep 21; JCO2017773648.
View in: PubMed

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018 11; 93(11):1301-1310.
View in: PubMed

Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. Am J Hematol. 2018 10; 93(10):1254-1266.
View in: PubMed

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 09; 16(9):1108-1135.
View in: PubMed

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
View in: PubMed

Single 6-mg dose of rasburicase: The experience in a large academic medical center. J Oncol Pharm Pract. 2019 Sep; 25(6):1349-1356.
View in: PubMed

Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. J Clin Pathol. 2019 01; 72(1):93-96.
View in: PubMed

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018 09 13; 132(11):1125-1133.
View in: PubMed

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018 05; 118(11):1425-1433.
View in: PubMed

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
View in: PubMed

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. JAMA Oncol. 2018 05 01; 4(5):725-734.
View in: PubMed

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018 04 11; 10(436).
View in: PubMed

Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018 Jul; 71(7):653-658.
View in: PubMed

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
View in: PubMed

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected. Oncol Ther. 2018 Jun; 6(1):9-20.
View in: PubMed

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 03 07; 10(431).
View in: PubMed

How to treat chronic myeloid leukemia (CML) in older adults. J Geriatr Oncol. 2018 07; 9(4):291-295.
View in: PubMed

The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018 Feb; 45(2):306-314.
View in: PubMed

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
View in: PubMed

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 01 25; 131(4):387-396.
View in: PubMed

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
View in: PubMed

A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017 Nov 01; 9(414).
View in: PubMed

Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol. 2017 12; 10(12):1033-1045.
View in: PubMed

Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. Br J Haematol. 2017 12; 179(5):705-723.
View in: PubMed

Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv. 2017 Sep 26; 1(21):1786-1789.
View in: PubMed

Neutrophil Fc?RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. J Clin Invest. 2017 Oct 02; 127(10):3810-3826.
View in: PubMed

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 09; 15(9):1091-1102.
View in: PubMed

Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. Curr Hematol Malig Rep. 2017 08; 12(4):370-379.
View in: PubMed

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018 02; 32(2):470-478.
View in: PubMed

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug; 4(8):e387-e398.
View in: PubMed

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2017 Jun 27; 1(15):1167-1180.
View in: PubMed

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 08 10; 130(6):722-731.
View in: PubMed

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ?30% blasts. Leukemia. 2017 12; 31(12):2799-2806.
View in: PubMed

Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology. 2017 Jul; 71(1):112-124.
View in: PubMed

Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566.
View in: PubMed

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313.
View in: PubMed

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J. 2017 02 03; 7(2):e520.
View in: PubMed

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017 Jan 24; 1(5):331-340.
View in: PubMed

Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia. J Clin Oncol. 2017 Feb 20; 35(6):583-586.
View in: PubMed

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
View in: PubMed

NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512.
View in: PubMed

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. Ther Adv Hematol. 2017 Jan; 8(1):3-12.
View in: PubMed

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia. 2017 01; 31(1):34-39.
View in: PubMed

Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest. 2016 10 03; 126(10):3827-3836.
View in: PubMed

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 06 27; 213(7):1285-306.
View in: PubMed

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016 Aug 25; 375(8):740-53.
View in: PubMed

Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9.
View in: PubMed

Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
View in: PubMed

Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
View in: PubMed

Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12; 7(15):20152-65.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar; 91(3):322-9.
View in: PubMed

Evolving Therapies in Acute Myeloid Leukemia: Progress at Last? Am Soc Clin Oncol Educ Book. 2016; 35:e302-12.
View in: PubMed

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood Cancer J. 2015 Dec 11; 5:e375.
View in: PubMed

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Rep. 2015 Dec 22; 13(11):2345-2352.
View in: PubMed

Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99.
View in: PubMed

Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206.
View in: PubMed

Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the ?-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000539.
View in: PubMed

Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. Cold Spring Harb Mol Case Stud. 2015 Oct; 1(1):a000307.
View in: PubMed

Acute Lymphoblastic Leukemia, Version 2.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1240-79.
View in: PubMed

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.
View in: PubMed

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2016 Jan; 30(1):219-28.
View in: PubMed

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
View in: PubMed

Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities. Br J Dermatol. 2015 Aug; 173(2):574-7.
View in: PubMed

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in: PubMed

Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous Leukemia. Open Forum Infect Dis. 2015 Sep; 2(3):ofv096.
View in: PubMed

Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98.
View in: PubMed

Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol. 2015 Jul; 28(7):965-76.
View in: PubMed

Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
View in: PubMed

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015 May; 169(4):534-43.
View in: PubMed

The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy. Leukemia. 2015 Jun; 29(6):1320-30.
View in: PubMed

The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2015; 2015:400-5.
View in: PubMed

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
View in: PubMed

Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015 Feb; 39(2):204-10.
View in: PubMed

One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin. 2015 Feb; 31(2):315-22.
View in: PubMed

Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw. 2014 Nov; 12(11):1590-610.
View in: PubMed

A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One. 2014; 9(10):e108694.
View in: PubMed

Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol. 2015 Jan; 168(2):230-8.
View in: PubMed

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34.
View in: PubMed

De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
View in: PubMed

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87.
View in: PubMed

Switching drugs midstream for patients with chronic myeloid leukemia. Clin Adv Hematol Oncol. 2014 Jul; 12(7):466-8.
View in: PubMed

The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32.
View in: PubMed

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014 Mar; 89(3):237-42.
View in: PubMed

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25.
View in: PubMed

SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10; 25(2):226-42.
View in: PubMed

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014 Apr 01; 120(7):1010-7.
View in: PubMed

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 06; 123(6):905-13.
View in: PubMed

Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):245-51.
View in: PubMed

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar; 4(3):362-75.
View in: PubMed

A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45.
View in: PubMed

A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
View in: PubMed

Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw. 2013 Nov; 11(11):1327-40.
View in: PubMed

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96.
View in: PubMed

Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer. 2013 Oct 01; 119(19):3472-8.
View in: PubMed

Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One. 2013; 8(6):e67306.
View in: PubMed

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
View in: PubMed

Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. J Oncol Pract. 2013 Sep; 9(5):e228-33.
View in: PubMed

Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003.
View in: PubMed

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35.
View in: PubMed

Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res. 2013 Jul; 37(7):747-51.
View in: PubMed

Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase. Clin Chem Lab Med. 2013 May; 51(5):1053-7.
View in: PubMed

SYK regulates mTOR signaling in AML. Leukemia. 2013 Nov; 27(11):2118-28.
View in: PubMed

Resistance revealed in acute lymphoblastic leukemia. Nat Med. 2013 Mar; 19(3):264-5.
View in: PubMed

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013 Aug; 27(8):1628-36.
View in: PubMed

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood. 2013 Mar 28; 121(13):2393-401.
View in: PubMed

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013 Mar 01; 31(7):923-9.
View in: PubMed

An extreme example of focal bone marrow involvement in acute myeloid leukemia. Am J Hematol. 2013 Apr; 88(4):335-6.
View in: PubMed

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy. Blood Cancer J. 2012 Oct 19; 2:e95.
View in: PubMed

Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012 Oct 12; 151(2):344-55.
View in: PubMed

Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
View in: PubMed

Acute lymphoblastic leukemia. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):858-914.
View in: PubMed

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013 Jan 01; 119(1):90-8.
View in: PubMed

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8.
View in: PubMed

The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47.
View in: PubMed

Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2012 Jan; 10(1):64-110.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

Chronic myelogenous leukemia. Preface. Hematol Oncol Clin North Am. 2011 Oct; 25(5):ix-x.
View in: PubMed

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol. 2011 Sep; 86(9):811-9.
View in: PubMed

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
View in: PubMed

Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):375-7.
View in: PubMed

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7.
View in: PubMed

Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5.
View in: PubMed

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011 Jun; 27(6):1263-71.
View in: PubMed

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1121-31.
View in: PubMed

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets. 2011 Mar; 15(3):253-64.
View in: PubMed

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9.
View in: PubMed

An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol. 2010 Dec; 85(12):944-6.
View in: PubMed

Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7.
View in: PubMed

Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol. 2010 Sep; 85(9):695-9.
View in: PubMed

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 01; 28(28):4339-45.
View in: PubMed

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12617-22.
View in: PubMed

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
View in: PubMed

NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1037-69.
View in: PubMed

When to go FISHing. Am J Clin Pathol. 2010 Mar; 133(3):351-3.
View in: PubMed

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leuk Lymphoma. 2010 Mar; 51(3):363-75.
View in: PubMed

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
View in: PubMed

Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1121-35, vii-viii.
View in: PubMed

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009 Oct; 7(9):984-1023.
View in: PubMed

Screens, iron, and leukemia. Blood. 2009 Oct 01; 114(14):2857-8.
View in: PubMed

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.
View in: PubMed

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol. 2009 Oct; 147(1):97-101.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45.
View in: PubMed

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
View in: PubMed

Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine. J Clin Oncol. 2009 May 20; 27(15_suppl):7050.
View in: PubMed

A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol. 2009 May 20; 27(15_suppl):3579.
View in: PubMed

Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205.
View in: PubMed

A forgotten cause of kidney injury in chronic myelomonocytic leukemia. Am J Kidney Dis. 2009 Jul; 54(1):159-64.
View in: PubMed

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
View in: PubMed

Disease response to the histone deacetylase inhibitor panobinostat in refractory hodgkin lymphoma. 2008; submitted.

A forgotten cause of renal failure in chronic myelomonocytic leukemia. 2008; submitted.

A dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. 2008; submitted.

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7.
View in: PubMed

Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer. 2008 Oct; 47(10):884-9.
View in: PubMed

A novel SSBP2-JAK2 fusion gene as a result of t(5;9)(q14.3;p24.1) in precursor-B acute lymphocytic leukemia. Cancer Genet Cytogenet. 2008; in press.

Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia. J Clin Oncol. 2008 Aug 01; 26(22):3804-7.
View in: PubMed

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
View in: PubMed

Nelarabine for relapsed t-cell acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy. 2008; in press.

New agents in acute lymphoblastic leukemia. Current Hematologic Malignancy Reports. 2008; 3(3):in press.

Myelodysplastic Syndromes: Biology and Treatment. Hoffmann R, Benz EJ Jr., Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 2008; in press.

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M (Cloretazine) in patients (pts) with first relapse of acute myeloid leukemia (AML). American Society of Clinical Oncology (ASCO). 2008; in press.

New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2008 Jul; 3(3):135-43.
View in: PubMed

Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81.
View in: PubMed

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Sep; 22(9):1707-11.
View in: PubMed

Clinical problem-solving. A joint venture. N Engl J Med. 2008 Jun 05; 358(23):2496-501.
View in: PubMed

Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol. 2008 Jun; 83(6):519-20.
View in: PubMed

Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hematologic malignancies at high or potential risk for tumor lysis syndrome. J Clin Oncol. 2008 May 20; 26(15_suppl):14545.
View in: PubMed

A Phase II study of VNP40101M in elderly patients (pts) with de novo poor risk acute myelogenous leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7026.
View in: PubMed

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7051.
View in: PubMed

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54.
View in: PubMed

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol. 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20.
View in: PubMed

Hematology-Oncology. Sabatine MS, ed. Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine. 2008; 5-1 to 5-36.

Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007 Dec 24; 204(13):3059-66.
View in: PubMed

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies. Blood. 2007; 110(11):276a.

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. Blood. 2007; 110(11):53a.

JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations. Blood. 2007; 110(11):487a.

II Study of VNP40101M (Cloretazine) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML). Blood. 2007; 110(11):279a.

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial. Blood. 2007; 110(11):1035A.

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. Blood. 2007; 110(11):195B.

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. Blood. 2007; 110(11):181a.

A t(4;12)(q11;p13) in a patient with coincident CLL at the same time of AML diagnosis. Atlas Genet Cytogenet Oncol Haematol. 2007.

Role of imatinib-sensitive tyrosine kinases in the pathogenesis of chronic myeloproliferative disorders. Seminars in Oncology. 2007; 44(2 Suppl 2):S17-30.

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in: PubMed

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42.
View in: PubMed

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007 Mar 01; 25(7):813-9.
View in: PubMed

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007 Jan; 13(1):78-83.
View in: PubMed

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in: PubMed

Systemic mastocytosis: current classification and novel therapeutic options. Clin Adv Hematol Oncol. 2006 Oct; 4(10):768-75.
View in: PubMed

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604.
View in: PubMed

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 01; 108(12):3674-81.
View in: PubMed

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15; 108(10):3477-83.
View in: PubMed

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul; 3(7):e270.
View in: PubMed

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6585.
View in: PubMed

Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2025.
View in: PubMed

Outcome of adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols, 1991-2000. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9023.
View in: PubMed

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine® in patients with first relapse of acute myeloid leukemia (AML). Blood. 2006; 108(11):557a.

Metabolic emergencies in oncology. Chang A, Ganz P, Hayes D, Kinsella T, Pass H, Schiller J, Stone R, Strecher V, eds. Oncology: an evidence-based approach. 2006; 1312-22.

Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood. 2006; 108(11):50a.

Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function. Journal of Clinical Oncology. 2006; 24(18s):85s.

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology. 2006; 24(18s):357s.

Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). [Oral presentation]. Blood. 2006; 108(11):51a.

Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2005 Oct 01; 162(1):89-91.
View in: PubMed

The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005 Aug 15; 65(16):7338-47.
View in: PubMed

Is the cryptic interstitial deletion of 8q24 surrounding MYC a common mechanism in the formation of double minute chromosome? Cancer Genet Cytogenet. 2005 Aug; 161(1):90-2.
View in: PubMed

Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005 Oct 15; 106(8):2841-8.
View in: PubMed

Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527.
View in: PubMed

Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):3131.
View in: PubMed

Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT). J Clin Oncol. 2005 Jun; 23(16_suppl):6539.
View in: PubMed

Molecularly Targeted Therapies for the Treatment of Acute Myeloid Leukemia. Blumenthal RS, Coombs J, Fennerty B, Goodnight-White S, Kemp J, Kendall D, Lublin F, Mace SE, Wilkens R, eds. Targeted Therapies: Advances in the Treatment of Acute Myeloid Leukemia. 2005; 2(1):17-20.

Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94.
View in: PubMed

Managing Chronic Myelogenous Leukemia: An Update. A CE-Certified Activity for Physicians and Nurses. 2005.

Diagnosis of an early precursor-B-ALL presenting with hypereosinophilia using FISH on immunomagnetically selected CD19+ cells [commentary]. Clin Adv Hematol Oncol. 2005; 3(1):64-9.

Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2005; 106(11):121a.

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005 Jan; 19(1):27-30.
View in: PubMed

The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005; 123-30.
View in: PubMed

Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. Journal of Clinical Oncology. 2005; 23(16s):224s.

The Era of Molecular Therapy: Focus on Chronic Myelogenous Leukemia. 2005.

Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT). Journal of Clinical Oncology. 2005; 23(16s):569s.

A randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients <60 years using p-glycoprotein (Pgp) modulation with valspodar (PSC833): preliminary results of cancer and leukemia group B study 19808. Blood. 2005; 106(11):122a.

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Onc. 2005; 23:4110-6.

Myelodysplastic Syndromes: Biology and Management. Hoffmann R, Benz EJ Jr., Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 2005; 1195-1208.

Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC leukemia fusion cells as a tumor vaccine for AML. Blood. 2005; 106(11):782a.

Review. Clin Adv Hematol Oncol. 2005 Jan; 3(1):64-9.
View in: PubMed

Patient Management Issues with Imatinib Mesylate in CML and Other Hematologic Malignancies. Novel Agents in the Leukemias. 2004.

Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12.
View in: PubMed

The Era of Molecular Therapy: Focus on Chronic Myelogenous Leukemia. 2004.

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
View in: PubMed

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004 Oct 05; 101(40):14479-84.
View in: PubMed

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005 Jan 01; 105(1):22-30.
View in: PubMed

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005 Jan 01; 105(1):54-60.
View in: PubMed

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
View in: PubMed

A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3024.
View in: PubMed

Posttransplant immunotherapy with a GM-CSF-based tumor vaccine following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML). J Clin Oncol. 2004 Jul 15; 22(14_suppl):6545.
View in: PubMed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in: PubMed

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004 Apr; 18(4):809-16.
View in: PubMed

Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer? Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):1-3.
View in: PubMed

PKC 412 FLT3 inhibitor therapy in AML: Results of a phase II trial. Annals of Hematology. 2004; 83(Suppl 1):S89-90.

Karyotypic evolution in patients receiving imatinib: an interesting observation or a new problem? [commentary]. American Journal of Oncology Review. 2004; 3(2):110-112.

Hematology-Oncology. Sabatine MS, ed. Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine. 2004; 5-1 to 5-35.

Decision-making and quality-of-life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004; 18(4):809-16.

Therapy-related myelodysplastic syndrome; More is not always better [commentary]. American Journal of Oncology Review. 2004; 3(5):305-8.

Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003 Nov 01; 102(9):3455-6.
View in: PubMed

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
View in: PubMed

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69.
View in: PubMed

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14.
View in: PubMed

Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. Am J Ophthalmol. 2003 Mar; 135(3):398-400.
View in: PubMed

Tumor Lysis Syndrome. Furie B, Cassileth P, Mayer R, Atkins, eds. Clinical Practice of Hematology and Oncology. 2003; 117:1187-90.

Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in: PubMed

Induction chemotherapy with daunorubicin, cytarabine, and gemtuzumab ozogamicin in acute myeloid leukemia. Case Studies in Leukemia. 2002.

Comparable outcome with T-cell deleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Mar Transplant. 2002; 8:601-7.

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.
View in: PubMed

A new case of isolated del(12)(q15q22) in myelodysplastic syndrome. Cancer Genet Cytogenet. 2001 Oct 01; 130(1):89-91.
View in: PubMed

Harrison’s Principles of Internal Medicine Self-Assessment and Board Review (RM Stone, editor). 2001.

Hematology-Oncology. Sabatine MS, ed. Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine. 2000; 5-1 to 5-31.

Myelodysplasia in adults: current status of care [review]. Adv Onc. 2000; 16:21-6.

Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998 Sep; 4(9):1046-52.
View in: PubMed

Patient selection reduces thrombotic complications of emergent stenting for failed PTCA. Cathet Cardiovasc Diagn. 1995 Apr; 34(4):286-92.
View in: PubMed

The embryonic enhancer-binding protein SSAP contains a novel DNA-binding domain which has homology to several RNA-binding proteins. Mol Cell Biol. 1995 Mar; 15(3):1254-64.
View in: PubMed

The embryonic enhancer binding protein, SSAP, contains a novel DNA binding domain, which shares homology to a number of RNA binding proteins. Mol Cell Biol. 1995; 15:1254-64.

Purification and characterization of the stage-specific embryonic enhancer-binding protein SSAP-1. Mol Cell Biol. 1993 Mar; 13(3):1746-58.
View in: PubMed

The purification, characterization, and cloning of an embryonic enhancer protein. 1993.

An embryonic enhancer determines the temporal activation of a sea urchin late H1 gene. Mol Cell Biol. 1989 Jun; 9(6):2315-21.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana D1B30
Boston, MA 02215
Get Directions

Ratings

Top